Literature DB >> 12460204

Ki67 antigen and PCNA proliferation markers predict survival in anorectal malignant melanoma.

O Ben-Izhak1, M Bar-Chana, L Sussman, V Dobiner, J Sandbank, M Cagnano, H Cohen, E Sabo.   

Abstract

AIMS: To find a possible correlation of Ki67 antigen and proliferating cell nuclear antigen (PCNA) with prognosis in anorectal malignant melanoma. METHODS AND
RESULTS: Thirty patients with anorectal malignant melanoma were studied. The percentage of tumour cells stained for Ki67 and PCNA in paraffin sections was assessed. Mode of treatment (local excision or abdominoperineal resection), depth of tumour invasion, attempt at cure as defined by complete tumour excision and absence of distant metastases at presentation, tumour blood vessel invasion, and tumour necrosis, as well as Ki67 and PCNA, were all correlated with survival. By univariate analysis, PCNA, Ki67, attempt at cure, local excision (and not abdominoperineal resection), and depth of invasion were all significantly associated with longer survival. By multivariate analysis, only PCNA was significantly associated with survival, while Ki67 showed a significant positive correlation with PCNA. With a cut-off point of 40%, patients with lower Ki67 scores showed survival advantage over those with higher Ki67 scores (P=0.0004). With a cut-off point of 80%, patients with lower PCNA scores showed survival advantage over those with higher PCNA scores (P=0.0001). The staining for proliferation markers was also associated with depth of tumour invasion.
CONCLUSIONS: Ki67 and PCNA immunostaining in paraffin sections may be useful for the prediction of survival in patients with anorectal malignant melanoma. Larger studies are needed to confirm our results.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12460204     DOI: 10.1046/j.1365-2559.2002.01444.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  24 in total

1.  Anorectal Malignant Melanoma-Defining the Optimal Surgical Treatment and Prognostic Factors.

Authors:  Syed Nusrath; Subramanyeshwar Rao Thammineedi; Sujit Chyau Patnaik; K V V N Raju; Satish Pawar; Vipin Goel; Ramachandra Nagaraju Chavali; Sudha Murthy
Journal:  Indian J Surg Oncol       Date:  2018-07-23

2.  Anorectal melanoma.

Authors:  Amalia Stefanou; Surya P M Nalamati
Journal:  Clin Colon Rectal Surg       Date:  2011-09

3.  The novel cytokine p43 stimulates dermal fibroblast proliferation and wound repair.

Authors:  Sang Gyu Park; Hyosook Shin; Young Kee Shin; Yeonsook Lee; Eung-Chil Choi; Bum-Joon Park; Sunghoon Kim
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

4.  Phosphorylation of proliferating cell nuclear antigen promotes cancer progression by activating the ATM/Akt/GSK3β/Snail signaling pathway.

Authors:  Bo Peng; Janice Ortega; Liya Gu; Zhijie Chang; Guo-Min Li
Journal:  J Biol Chem       Date:  2019-03-11       Impact factor: 5.157

5.  Anal melanoma.

Authors:  Marc Singer; Matthew G Mutch
Journal:  Clin Colon Rectal Surg       Date:  2006-05

6.  Isolation, establishment, and characterization of ex vivo equine melanoma cell cultures.

Authors:  Sarah W Kamau Chapman; Nadine Metzger; Paula Grest; Karsten Feige; Brigitte von Rechenberg; Jörg A Auer; Michael O Hottiger
Journal:  In Vitro Cell Dev Biol Anim       Date:  2008-12-05       Impact factor: 2.416

7.  Apoptosis is increased and cell proliferation is decreased in out-of-phase endometria from infertile and recurrent abortion patients.

Authors:  Gabriela F Meresman; Carla Olivares; Susana Vighi; Margarita Alfie; Marcela Irigoyen; Juan J Etchepareborda
Journal:  Reprod Biol Endocrinol       Date:  2010-10-22       Impact factor: 5.211

Review 8.  [Anorectal melanoma. A rare and highly malignant tumor entity of the anal canal].

Authors:  B M Helmke; H F Otto
Journal:  Pathologe       Date:  2004-05       Impact factor: 1.011

9.  Ki-67 index as a prognostic factor of subsequent lapatinib-based therapy in HER2-positive metastatic breast cancer with resistance to trastuzumab.

Authors:  Li Bian; Tao Wang; Shao-Hua Zhang; Hui-Qiang Zhang; Yun-Fei Guo; Ge Du; Wang Li; Shi-Kai Wu; San-Tai Song; Ze-Fei Jiang
Journal:  Cancer Biol Ther       Date:  2014-01-14       Impact factor: 4.742

10.  A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma.

Authors:  Dana Yip; Maithao N Le; Joseph L-K Chan; Jonathan H Lee; Janice A Mehnert; Anthony Yudd; Jeffery Kempf; Weichung J Shih; Suzie Chen; James S Goydos
Journal:  Clin Cancer Res       Date:  2009-05-19       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.